calcium intake or in compliance with treatment. Her calcium concentration returned to normal values after the dosage of 1›Æhydroxycholecalciferol was reduced to 1 g on alternate days. Further inquiry showed that her last menstrual period had been 3 months before the discovery of hypercalcaemia, and her postmeno› pausal status was confirmed by the finding of raised gonadotrophin concentrations (follicle stimulating hormone 93 U/l, luteinising hormone 109 U/l).

Case 3

A 51 year old woman had been treated with vitamin D analogues and thyroxine supplements for 13 years since developing persistent hypoparathyroidism and hypothyroidism after subtotal thyroidectomy for Graves' disease. Her serum calcium concentrations had been within the reference range until October 1988, when she presented with a 6 month history of weight loss of 9 kg, nausea, vomiting, thirst, and intermittent confusion. She was also menopausal. There had been no change in her dose of 1› Æhydroxycholecalciferol (2 g/day), calcium intake, or compliance with treatment. Hypercalcaemia was confirmed (the calcium concen› tration, adjusted for albumin, was 3.25 mmol/l). Her calcium concentration returned to normal and her symptoms resolved after intravenous rehydration treatment and an interval without vitamin D therapy. Treatment with 1› Æhydroxycholecalciferol was reintro› duced at a reduced daily dose of 0.25 g, and the patient's calcium concentrations remained within the reference range thereafter.

Comment

These three cases show that a change in oestrogen status can alter sensitivity to a potent vitamin D analogue in women who do not have the ability to produce parathyroid hormone. In a similar case, reported in 1979, a patient became hypercalcaemic after stopping the oral contraceptive pill.[2 3] Reintroduction of oestro› gen was associated with a fall in her serum calcium con› centration. The anti›oestrogenic activity of danazol — prescribed for endometriosis in a patient with idiopathic hypoparathyroidism who was being treated with 1› Æ hydroxycholecalciferol — resulted in hypercalcaemia and a reduced maintenance requirement for 1› Æhydroxyc› holecalciferol.[4] Hypercalcaemia can also occur immedi› ately after delivery in women with hypoparathyroidism treated with vitamin D supplements.[5 6] All these observations support a crucial role for oestrogen in cal› cium regulation in these women.

Oestrogen, 1,25›dihydroxyvitamin D, and parathy› roid hormone influence bone metabolism. Cytokines are now recognised as pivotal mediators of oestrogen, which acts on oestrogen receptors on osteoblasts[7] and osteoclasts[8] to inhibit bone resorption.[9] In normal women, oestrogen withdrawal increases bone resorp› tion and causes a rise in serum calcium. 1,25› dihydroxyvitamin D is now known to be the major direct regulator of active transcellular calcium absorp› tion via vitamin D receptors in intestinal mucosal cells.[10] Oestrogen can increase calcium absorption directly and indirectly by stimulating 1› Æhydroxylase activity in the kidney.[11] Withdrawal of oestrogens would theoretically reduce calcium absorption, and hypercal› caemia in these cases cannot be explained by this mechanism. Ultimately, the effects of oestrogen on bone and calcium metabolism are monitored by the calcium sensing receptor on parathyroid cells,[12] which respond by altering parathyroid hormone secretion. Parathyroid hormone is a major modulator of osteoclast activity. In the absence of parathyroid hormone, the positive effect on osteoclast activity and bone resorption of withdrawal of oestrogen becomes much more important for calcium regulation. In the absence of parathyroid hormone, the balance between the action of 1,25›dihydroxyvitamin D, which is a potent inducer of bone resorption,[13] and of oestrogen, which inhibits bone resorption, may become more crucial. A clinical awareness of this phenomenon allows appropriate monitoring of patients and adjustment of their dose of vitamin D at the menopause or while starting or stopping hormone replacement therapy.

Contributors: JM, RD and AA collected cases. JM, FD and JH wrote the manuscript and are guarantors for the paper.

1 Gann DS, Paone JF, Delayed hypocalcemia after thyroidectomy for Graves' disease is prevented by parathyroid autotransplanation. Ann Surg 1979;190:508›13.
2 Verbeelen D, Fuss M. Hypercalcaemia induced by oestrogen withdrawal in vitamin D›treated hypoparathyroidism. BMJ 1979;i:522›3.
3 Nagant de Deuxchaisnes C. Oestrogen›induced hypocalcaemia in hypoparathyroidism. BMJ 1979;i:1563.
4 Hepburn NC, Abdul›Aziz LAS, Whiteoak R. Danazol›induced hypercal› caemia in alphacalcidol›treated hypoparathyoidism. Postgrad Med J 1989;65:849›50.
5 Cundy T, Haining SA, Guilland›Cumming DF, Butler J, Kanis JA. Remis› sion of hypoparathyroidism during lactation: evidence for a physiological role for prolactin in the regulation of vitamin D metabolism. Clin Endocrinol 1987;26:667›74.
6 Wright AD, Joplin GF, Dixon HG. Postpartum hypercalcaemia in treated hypoparathyroidism. BMJ 1969;i:23›5.
7 Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, et al. Evidence of oestrogen receptors on normal human osteoblast›like cells. Science 1988:241;84›6.
8 Oursler MJ, Pederson L, Pyfferoen J, Osdoby P, Fitzpatrick L, Spelsberg TC. Oestrogen modulation of avian osteoclast lysosomal gene expression. Endocrinology 1993;132:1373›80.
9 Manolagas SC, Jilka RL. Bone marrow cytokines and bone remodelling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305›11.
10 Reichel H, Koeffler HP, Norman AW. Role of vitamin D endocrine system in health and disease. N Engl J Med 1989;320:980.
11 Gennari C, Agnusdei D, Nardi P, Givirelli R. Estrogen preserves a normal intestinal responsiveness to 1,25›dihydroxyvitamin D3 in oophorect› omized women J Clin Endocrinol Metab 1990;71:1288›93.
12 Brown EM, Gamba G, Riccardi D, Lambardi M, Butters R, Kifor O, et al. Cloning and characterisation of an extracellular calcium sensing receptor from bovine parathyroid. Nature 1993;366:575›80.
13 Reynolds JJ, Pavlovitch H, Balsan S. 1,25›dihydroxycholecalciferol increases bone resorption on thyroparathyroidectomised mice. Calcified Tiss Res 1976;21:207›12.

(Accepted 12 May 1999)

University Department of Medicine, Glasgow Royal Infirmary
John Hinnie lecturer
Rosemary Dargie clinical assistant
Alaa Al›Rawi senior house officer
Correspondence to: J McIlroy JMcIlroy@gri› biochem.org.uk

Corrections and clarifications

Screening of newborn infants for cholestatic hepatobiliary disease with tandem mass spectrometry
In this paper by I Mushtaq et al (21 August, pp 471›7) the x axis in figure 3 should have been labelled 1›specificity.

Minerva
Minerva has made a mistake—the fourth paragraph in the issue of 2 October reports a trial of cognitive behaviour therapy in depression. It was published in Archives of General Psychiatry 1999;56:829›35 (not the British Journal of Psychiatry).

Letters
In the letter by Philip C Herbert (26 June, p 1762), a wrong currency conversion was given. $C40 000 is equivalent to about £16 300 [not £92 000].